Pharmacokinetics of a 1,000 mg Disintegrating Aspirin Tablet Formulation

Migraine is a global disorder and considerably affecting people`s quality of life. Treatments include nonsteroidal anti-inflammatory drugs-containing medicinal products among whom acetylsalicylic acid-containing Aspirin® has been proven effectively to relief migraine headache. Early treatment is recommended for patients with migraine attacks. A requirement for early onset of action includes tablet disintegration and consequent active ingredient dissolution and absorption. The bioavailability of a new quickly disintegrating 1,000 mg aspirin formulation has been investigated in a bioequivalence study versus a marketed Aspirin® formulation with clinically demonstrated early onset of action. The new formulation has a tablet strength (1,000 mg) and time to maximum plasma concentration (mean 21.6 minutes) providing upside for people requiring treatment of migraine headache